STAT+: ARCH-launched Neumora stops depression program

Neumora Therapeutics announced on March 18, 2024, that it is discontinuing its Phase 2b clinical trial for its lead depression drug, potentially impacting its valuation and future development. The company, backed by ARCH Venture Partners, stated that the decision was made after a review of the trial's data, though specific details regarding efficacy or safety concerns were not immediately disclosed. This setback represents a significant challenge for Neumora, which had positioned this drug as a key component of its pipeline aimed at addressing neurological and psychiatric conditions. The company's stock experienced a notable decline following the announcement, reflecting investor concerns about the future of its research and development efforts. Neumora had previously reported positive early-stage data for the drug, leading to high expectations for its performance in later-stage trials. The discontinuation raises questions about the scientific approach and the broader market for novel depression treatments. The company stated it will provide further updates on its strategic priorities during its upcoming investor call.